China Kanghui Holdings
Smith & Nephew (NYSE:SNN) won a nod from the FDA for its Pico negative-pressure wound therapy system.
The British orthopedics giant’s wound care division said the FDA cleared the device for use in the home and in hospitals. It’s already on the market in Europe, Canada and Australia, according to a press release.
China Kanghui Holdings (NYSE:KH), a Chinese orthopedic implant maker that went public on the New York Stock Exchange last year, bought out a majority stake of a fellow Chinese implant maker, a move China Kanghui said will make it a player in both the Chinese and international markets by 2014.
The Changzhou, China-based device company said in a regulatory filing that it picked up a 60 percent interest in Beijing Wei Rui Li Medical Device Co. Ltd., a maker of hip and knee systems.